Skip to main content

Table 1 Study population characteristics

From: Real-world effectiveness of long-acting injections for reducing recurrent hospitalizations in patients with schizophrenia

 PatientsEpisodes
Total75,274132,028
Mean age (years)40.3 ± 12.0 
Sex
 Male35,103 (46.6%) 
 Female40,171 (53.4%) 
Diagnosis
 F20 Schizophrenia 121,884 (92.3%)
 F25 Schizoaffective disorder 10,144 (7.7%)
Hospital of discharge
 Tertiary 18,182 (13.8%)
 General 19,114 (14.5%)
 Clinic or other 94,732 (71.8%)
Duration of admission (days) 40 (24–67)
Observation period (days) 369 (103–1004)
Sum of periods (person-years)
 All 255,664
 Non-medication 80,104
 Oral alone 169,948
 LAI 5612
Number of episodes
 147,535 (63.1%) 
 214,962 (19.9%) 
 36200 (8.2%) 
 4 or more6577 (8.7%) 
Outcome event 101,589 (76.9%)
 Death 1795
 Readmission 99,794
 F20 Schizophrenia 66,560 (66.7%)
 F25 Schizoaffective disorder 5448 (5.5%)
 F20–29 except F20 and F25 1393 (1.4%)
 F00–F99 except F20-F29 5834 (5.8%)
 Other codes 20,559 (20.6%)
  1. LAI long-acting injection